Previous studies have shown that reduced levels of the antagonistic metabolite and increased amounts of active GLP-1 can be achieved by inhibiting DPP-IV enzyme activity, which could be beneficial in the treatment of impaired glucose tolerance and Type 2 diabetes. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.